Wall Street brokerages expect ICU Medical, Incorporated (NASDAQ:ICUI) to report earnings per share (EPS) of $0.98 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for ICU Medical’s earnings. The lowest EPS estimate is $0.92 and the highest is $1.04. ICU Medical posted earnings of $1.20 per share in the same quarter last year, which suggests a negative year over year growth rate of 18.3%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, March 1st.
On average, analysts expect that ICU Medical will report full-year earnings of $4.57 per share for the current fiscal year, with EPS estimates ranging from $4.45 to $4.70. For the next financial year, analysts forecast that the firm will post earnings of $6.61 per share, with EPS estimates ranging from $6.35 to $6.92. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow ICU Medical.
Separately, Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $266.00 target price for the company in a research report on Tuesday, January 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. ICU Medical currently has an average rating of “Hold” and a consensus target price of $266.00.
Institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its stake in ICU Medical by 4.0% during the second quarter. Ameritas Investment Partners Inc. now owns 1,321 shares of the medical instruments supplier’s stock worth $228,000 after buying an additional 51 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in ICU Medical by 1.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,468 shares of the medical instruments supplier’s stock worth $1,979,000 after purchasing an additional 146 shares in the last quarter. Suntrust Banks Inc. raised its stake in ICU Medical by 1.7% in the 4th quarter. Suntrust Banks Inc. now owns 14,617 shares of the medical instruments supplier’s stock worth $3,157,000 after purchasing an additional 239 shares in the last quarter. Public Employees Retirement Association of Colorado raised its stake in ICU Medical by 0.3% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 100,334 shares of the medical instruments supplier’s stock worth $21,672,000 after purchasing an additional 254 shares in the last quarter. Finally, Profund Advisors LLC raised its stake in ICU Medical by 18.1% in the 4th quarter. Profund Advisors LLC now owns 1,804 shares of the medical instruments supplier’s stock worth $390,000 after purchasing an additional 276 shares in the last quarter. 75.52% of the stock is owned by institutional investors and hedge funds.
ICU Medical (NASDAQ:ICUI) traded up $1.95 during trading on Monday, reaching $227.15. 77,900 shares of the company’s stock were exchanged, compared to its average volume of 91,074. The firm has a market cap of $4,533.40, a price-to-earnings ratio of 147.50, a price-to-earnings-growth ratio of 2.38 and a beta of 0.42. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65. ICU Medical has a 52-week low of $142.01 and a 52-week high of $240.20.
TRADEMARK VIOLATION WARNING: “” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/1882327-2/1882327.html.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.